

PRESS RELEASE

innate pharma

This press release may not be distributed directly or indirectly in Canada, Australia or Japan. This press release is not offering material and is for information purposes only.

INNATE PHARMA RAISES 50 MILLION EUROS IN A CAPITAL INCREASE SUBSCRIBED BY SPECIALIST INSTITUTIONAL INVESTORS

Marseille, France, June 24, 2014

Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases (the “Company”), announces today the completion of a capital increase directed to specialist institutional investors.

The gross amount raised is 50 million euros corresponding to 6.25 million new ordinary shares which will be issued. The subscription price of each new share is €8.0, corresponding to a 11.7% discount to the volume-weighted average of the closing prices of the Company’s existing shares on the Euronext Paris stock exchange over the last five stock market trading days preceding the date upon which the issuance price is set, i.e. on June 23, 2014, in accordance with the sixteenth resolution of the Shareholders General Meeting of the Company dated March 27, 2014.


“This capital increase secures Innate Pharma’s cash horizon to the end of 2017 thereby assuring the full funding of five Phase II trials for NKG2A checkpoint inhibitor, as well as allowing the development of all other programs as planned”, said Hervé Brailly, CEO and co-founder of Innate Pharma. He added: *“We can now proceed with the generation of clinical data with this proprietary, first-in-class asset, with clinical trials starting this year in reference centers in North America and Europe.”*

About the capital increase

The capital increase was carried out without preferential subscription rights and reserved to the categories defined in the sixteenth resolution of the Shareholders General Meeting of the Company dated March 27, 2014, i.e.: (i) to industrial or commercial companies in the pharmaceutical / biotechnology sector, and (ii) to French or foreign investment funds investing in the pharmaceutical / biotech sector.

The capital increase amounts to 11.8% of the share capital of the Company as of today and represents a dilution of 13.4% for the existing shareholders.

The settlement and delivery of the new shares is expected to occur on June 26, 2014. Application will be made to list the new shares on Euronext Paris. A listing prospectus will be submitted to the French financial markets authority (*Autorité des Marchés Financiers*).



PRESS RELEASE

innate pharma

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in such forward-looking statements. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from forward-looking statements, please refer to the Risk Factors section of the Company's Registration Document (*Document de Référence*) filed with the AMF under registration No. D.14-0299 on April 7, 2014, which is available on the AMF website (www.amf-france.org) and on Innate Pharma's website.

This press release is for information purposes only and the information contained herein do not, and shall not, in any circumstances, constitute a public offering by Innate Pharma nor an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any jurisdiction, including France.


This press release does not constitute or form part of an offer or solicitation of an offer to buy or subscribe for securities in France. The securities referred to herein may not be and will not be offered or sold to the public in France.

This announcement is not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of November 4th, 2003, as amended, in particular by Directive 2010/73/UE in the extent such Directive has been transposed in the relevant member State of the European Economic Area (together, the "Prospectus Directive").

With respect to the member states of the European Economic Area which have implemented the Prospectus Directive (each, a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring the publication of a prospectus in any Relevant Member State. As a result, the securities may not and will not be offered in any Relevant Member State except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that Relevant Member State, or under any other circumstances which do not require the publication by Innate Pharma of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that Relevant Member State.

This press release is not an offer of securities for sale in the United States or any other jurisdiction. Securities may not be sold or offered in the United States unless they are registered or are exempt from the registration requirements of the U.S. Securities Act of 1933, as amended. Innate Pharma does not intend to register any portion of this offering in the United States or to conduct a public offering of securities in the United States.

In the United Kingdom, this press release is only being distributed to, and is only directed at, persons that (i) are "investment professionals" (falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). In the United Kingdom, this press release is directed only at relevant persons and must not be acted on or relied on by persons who are not



PRESS RELEASE

innate pharma

relevant persons. Any investment or investment activity to which this press release relates is available only to relevant persons and will be engaged in only with relevant persons.

The distribution of this document in certain countries may constitute a breach of applicable law. The persons in possession of this announcement shall then get knowledge of any local restrictions and shall comply with these restrictions.

The information contained in this document does not constitute an offer of securities for sale in the United States, Canada, Australia or Japan.

It may be unlawful to distribute this press release in certain jurisdictions. This press release is not for distribution in Canada, Japan or Australia.

For additional information, please contact:

Innate Pharma

Laure-Hélène Mercier

Director, Investor Relations

Phone: +33 (0)4 30 30 30 87

investors@innate-pharma.com

ATCG Press

Marielle Bricman

Mob.: +33 (0)6 26 94 18 53

mb@atcg-partners.com